Benign Prostatic Hyperplasia Clinical Trial
Official title:
Efficacy of Ultrasound Guided Percutaneous Transperineal Laser Ablation in Benign Prostatic Hypertrophy Patients: Non-Pharmacological Interventional Study
Efficacy of Ultrasound Guided Percutaneous Transperineal Laser Ablation in Benign Prostatic Hypertrophy Patients: Non-Pharmacological Interventional Study
Efficacy of Ultrasound Guided Percutaneous Transperineal Laser Ablation in Benign Prostatic
Hypertrophy Patients: Non-Pharmacological Interventional Study
The aim of this pilot study is to evaluate the efficacy of TPLA under US-guidance and the
safety and the reproducibility in acute and follow-up.
Objective of the study: Evaluate the efficacy of percutaneous ablative treatment with
neodymium laser; the complete profile of safety and tolerability in acute and in the
follow-up in patients with Benign Prostatic Hypertrophy by using multiparametric prostate MRI
that allows us to evaluate the prostate acutely after treatment and in follow-up. All of the
imaging data is correlated with clinical and laboratory data.
Design of the study: Non-pharmacological interventional study. The clinical evaluation will
be carried out at three different times:
Time 1: eligibility assessment, signing of informed consent Time 2: admission, laser ablation
and control with multiparametric MRI of the post-procedural prostate (T0).
Time 3 Follow up at 3 (T1) -6 (T2) -12 (T3) months from the procedure.
There are various inclusion and exclusion criteria. The inclusion criteria are: over 65 years
old, benign prostate hypertrophy (BPH) confirmed by pre-interventional multi-parametric
(mpMRI), moderate-elevated surgical risk, presence of urinary obstructive symptoms, signed
consent form. Exclusion criteria are: presence of prostate tumor diagnosed by MRI and
confirmed by biopsy, urethral stenosis, severe coagulation pathology, ischemic pathology,
pacemaker presence, inflammatory pathology in acute phase, presence of 3rd dominant lobe and
contraindication to MRI.
Pre-treatment blood chemistry tests:
- Total and fractionated PSA
- Complete blood count with platelet count and leukocyte formula
- Blood coagulation tests
- Urine test - urine culture
- Azotemia
- Creatinine
Technique of performing a percutaneous laser ablation treatment:
The treatments are performed by the radiology team, in an outpatient setting using the
Echolaser XVG combined system.
The procedure is performed with the patient in gynecological position, and in safe conditions
according to the current legislation for laser treatments (such as protective glasses).
Treatment includes local anesthesia of the perineal region, under ultrasound guidance. At the
discretion of the medical team, sedation can be carried out with anesthetic assistance.
2 or 4 needles of 21G, 1 or 2 will be inserted. In each needle a 300 micron optical fiber
will be inserted - Elesta s.r.l. - 50041, Calenzano (FI) - Italy, at a distance of 8-10 mm
from the urethra. For each ablation, for about 6 minutes, an energy of 1200 J per fiber will
be delivered, at the power of 2-5 Watts. At the end the needle and the fiber is retracted for
about 1 cm ("pull-back"). Further ablation follows, with delivery and duration and power
equal to the previous one. Depending on the size of the middle lobe one or more pull-backs
can be made. In total the treatment consists in dispensing up to 1800 J, at the power of 2-5
W for a total duration of 30 minutes.
The laser causes hyperthermia, denaturation and coagulative necrosis of proteins.
The maximum volume treated in a session and the extent of the ablation vary according to the
prostatic volume, anatomy and receptivity of the tissue.
At the end of the treatment 20 mg of corticosteroids ev (if not specifically contraindicated
by the patient) is administered, for anti-edema and anti-inflammatory purposes. An
antibiotic, pain relief and gastroprotective therapy is established for 1 week. After an
adequate observation period, the patient will be discharged.
Follow up: The clinical evaluation is carried out at different times
Post procedural follow up:
Immediately after the procedure, a multiparametric prostate MRI is performed, followed by
discharge with steroid therapy (prednisone), if not contraindicated, to be scaled and for
programming the subsequent follow-up phases.
Post-discharge follow-up:
Specialist examination, suprapubic ultrasound of the urinary tract (with evaluation of the
post-residual volume) and multiparametric prostate MRI at 3 months, 6 months and 12 months
and subsequent checks according to clinical judgment.
A urine test and any urine culture are attached to each clinical-ultrasound evaluation. At
each revaluation the IPSS form and the data collection form is filled out.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04807296 -
Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP)
|
N/A | |
Recruiting |
NCT05574244 -
Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction
|
N/A | |
Recruiting |
NCT04288427 -
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
|
N/A | |
Not yet recruiting |
NCT04245566 -
Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH
|
Phase 3 | |
Completed |
NCT02509975 -
Safety and Efficacy of OCL 503 in Prostate Artery Embolization
|
N/A | |
Completed |
NCT03246880 -
Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients
|
Phase 3 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Completed |
NCT02206243 -
Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
|
||
Completed |
NCT02283684 -
GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT
|
Phase 4 | |
Completed |
NCT01454349 -
Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)
|
Phase 1/Phase 2 | |
Completed |
NCT01438775 -
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
Completed |
NCT01139762 -
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
|
Phase 3 | |
Completed |
NCT01152190 -
A Study in Benign Prostatic Hyperplasia
|
Phase 3 | |
Active, not recruiting |
NCT00400894 -
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
|
N/A | |
Completed |
NCT00224133 -
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
|
Phase 3 | |
Unknown status |
NCT00381108 -
Study of the Effects of Pomegranate Tablets on Enlarged Prostates
|
Phase 1 | |
Completed |
NCT00701779 -
Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia
|
Phase 4 | |
Terminated |
NCT02962674 -
To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH.
|
N/A | |
Active, not recruiting |
NCT05415748 -
Deprescribing Tamsulosin in Older Men
|
Phase 4 | |
Recruiting |
NCT04853914 -
Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound.
|
N/A |